Valneva receives marketing authorization in europe for the world's first chikungunya vaccine, ixchiq®

Saint herblain (france), july 1, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the european commission (ec) has granted marketing authorization in europe for valneva's single-dose vaccine, ixchiq®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. the approval was unanimously endorsed by member states following a stringent assessment by the european medicines agency (ema)1. the ec decision marks the third approval the company has received for ixchiq® following approval from the u.s. food and drug administration (fda) in november 2023 and health canada last month2. the company expects to deliver the first doses in europe in the fourth quarter of 2024.
VALN Ratings Summary
VALN Quant Ranking